- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00793325
Long Term Use of Somatropin in Patients Small for Gestational Age
Special Investigation Of Long Term Use Of Genotropin For SGA (Regulatory Post Marketing Commitment Plan)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Patients need to be administered Somatropin (Genotropin®) in order to be enrolled in the surveillance.
Exclusion Criteria:
- Patients not administered Somatropin (Genotropin®).
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Somatropin
Patienter som administrerades somatropin.
|
Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants With Treatment Related Adverse Events.
Tidsram: Up to 3 years
|
Adverse events mean all unfavorable events that occur in participants after administration of somatropin, irrespective of causal relationship to somatropin (including clinically problematic abnormal changes in laboratory test values).
Treatment related adverse events were evaluated in company with the causal relationship to somatropin.
|
Up to 3 years
|
Number of Unlisted Treatment Related Adverse Events According to Japanese Package Insert.
Tidsram: Up to 3 years
|
Adverse events mean all unfavorable events that occur in participants after administration of somatropin, irrespective of causal relationship to somatropin (including clinically problematic abnormal changes in laboratory test values).
Treatment related adverse events were evaluated in company with the causal relationship to somatropin.
Unlisted treatment related adverse events were confirmed with listed adverse drug reaction according to Japanese package insert.
|
Up to 3 years
|
Number of Participants With Treatment Related Adverse Events of Somatropin: <15 Years of Age vs. >=15 Years of Age.
Tidsram: Up to 3 years
|
To determine whether age is a significant risk factor in the frequency of treatment related adverse events.
|
Up to 3 years
|
Number of Participants With Treatment Related Adverse Events of Somatropin by Gender.
Tidsram: Up to 3 years
|
To determine whether gender is a significant risk factor in the frequency of treatment related adverse events.
|
Up to 3 years
|
Number of Participants With Treatment Related Adverse Events of Somatropin Based on SGA Severity.
Tidsram: Up to 3 years
|
To determine whether severity of SGA is a significant risk factor in the frequency of treatment related adverse events.
The severity of SGA was comprehensively evaluated on the basis of information including height and weight at birth and height measured one year before the start of administration.
|
Up to 3 years
|
Number of Participants With Treatment Related Adverse Events of Somatropin: With Past History of Any Disease vs. Without Past History of Any Disease.
Tidsram: Up to 3 years
|
To determine whether past history of any disease is a significant risk factor in the frequency of treatment related adverse events.
|
Up to 3 years
|
Number of Participants With Treatment Related Adverse Events of Somatropin: With Complications vs. Without Complications
Tidsram: Up to 3 years
|
To determine whether having complication(s) is a significant risk factor in the frequency of treatment related adverse events.
|
Up to 3 years
|
Number of Participants With Treatment Related Adverse Events of Somatropin: With Hepatic Function Disorder vs. Without Hepatic Function Disorder.
Tidsram: Up to 3 years
|
To determine whether hepatic function disorder is a significant risk factor in the frequency of treatment related adverse events.
|
Up to 3 years
|
Number of Participants With Treatment Related Adverse Events of Somatropin: With Renal Impairment vs. Without Renal Impairment.
Tidsram: Up to 3 years
|
To determine whether renal impairment is a significant risk factor in the frequency of treatment related adverse events.
|
Up to 3 years
|
Number of Participants With Treatment Related Adverse Events of Somatropin: With Concomitant Drug(s) vs. Without Concomitant Drug(s).
Tidsram: Up to 3 years
|
To determine whether taking concomitant drug(s) is a significant risk factor in the frequency of treatment related adverse events.
|
Up to 3 years
|
Change in the Growth Rate Standard Deviation (SD) Score for Calendar Age.
Tidsram: Up to 3 years
|
Growth rate SD score = (Growth rate - Average growth rate for calendar age of gender) / SD score for growth rate for each calendar age of gender).
An SD score indicates how far a participant's score deviates from the mean of the reference population; an SD score higher than the mean gives a positive SD score whereas an SD score lower than the mean gives a negative SD score.
In addition, when the bone age was described, it was to be read as the calendar age for men who were 11 years or older and women who were 9 years or older, as necessary.
|
Up to 3 years
|
Change in Height SD Score for Calendar Age.
Tidsram: Up to 3 years
|
The change in height standard SD for calendar age = (Height SD score for each calendar age - Height SD score for calendar age of the previous year) / (the date on which the height was measured - the date of the previous year on which the height was measured) × 365.25.
|
Up to 3 years
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- A6281292
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Liten för graviditetsåldern
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, GermanyAvslutadSmall Gestational Age (SGA)
-
University of Colorado, DenverAvslutadPreeklampsi | Graviditetsdiabetes mellitus | Gestationell hypertoni | Förtidsleverans | Leverans av Small for Gestational Age (SGA) babyFörenta staterna
-
Aretaieion University HospitalAvslutadIschemi | Hepatektomi | Reperfusionsskada | Portvenen | Leverregenerering | Ligering | Small-For-Size leversyndrom | MjältartärGrekland
-
University College CorkCork University HospitalAvslutadFör tidig födelse av nyfödd | Undernäring; Intrauterin eller foster, Small-for-dates
Kliniska prövningar på Somatropin
-
Xiamen Amoytop Biotech Co., Ltd.Peking Union Medical College HospitalAvslutad
-
PfizerAktiv, inte rekryterandePrader-Willis syndromJapan
-
PfizerAvslutad
-
Novo Nordisk A/SAvslutadNoonans syndrom | Genetisk störningSverige
-
Novo Nordisk A/SAvslutadNoonans syndrom | Genetisk störningJapan
-
LG ChemAvslutadBiotillgänglighet, säkerhet och tolerabilitet bland olika Eutropinformuleringar hos friska frivilligaKorea, Republiken av
-
Novo Nordisk A/SAvslutadFostrets tillväxtproblem | Liten för graviditetsåldernJapan
-
Novo Nordisk A/SAvslutadAkondroplasi | Genetisk störningJapan
-
Novo Nordisk A/SAvslutadNoonans syndrom | Genetisk störningSverige
-
Novo Nordisk A/SAvslutadNoonans syndrom | Genetisk störningJapan